10月17日，海西新药（02637.HK）即将登陆港股市场。作为一家仿创结合的医药企业，海西新药的业务呈现“双轮驱动”的模式：即一边依靠成熟的仿制药业务构筑了稳健的现金流，另一边则是凭借创新药管线为公司带来巨大的想象空间。与Biotech相比，这种“一手拉着过去，一手拉着未来”的业务布局，是无数中国药企在当下转型期的真实写照，同时也让海西新药的上市充满了看点。01仿制药基本盘——稳健的“现金奶牛”...
Source Link10月17日，海西新药（02637.HK）即将登陆港股市场。作为一家仿创结合的医药企业，海西新药的业务呈现“双轮驱动”的模式：即一边依靠成熟的仿制药业务构筑了稳健的现金流，另一边则是凭借创新药管线为公司带来巨大的想象空间。与Biotech相比，这种“一手拉着过去，一手拉着未来”的业务布局，是无数中国药企在当下转型期的真实写照，同时也让海西新药的上市充满了看点。01仿制药基本盘——稳健的“现金奶牛”...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.